# Biametrics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/biametrics

- Industry: Biotechnology
- Headquarters: Tubingen, Germany
- Website: www.biametrics.com
- Total disclosed funding: $4.2M
- Latest round: Series A (Aug 3, 2015)
- Investors on record: 5

## About

Biametrics is a biotechnology company specializing in advanced laboratory solutions, including innovative protein binding technologies designed to enhance research efficiency for biopharmaceuticals and diagnostics.Founded in 2010 in Tubingen, Germany, Biametrics focuses on laboratory technologies without any reported changes in business operations. The company has executed three deals, with the most recent transaction occurring on February 12, 2018, during its Series A funding round, where it raised EUR 3.10 mn from lead investor High-Tech Gründerfonds and others. The CEO, Steffen Hüttner, leads the company, which has not been noted as a subsidiary of any parent organization.Biametrics Circadian Kronos specializes in advanced laboratory solutions, prominently featuring its innovative protein binding workstation, the Versa bscreen, which operates in a label-free kinetic binding environment. This workstation is designed to enhance the efficiency and accuracy of binding assays, catering to the research needs of biopharmaceutical companies, academic institutions, and clinical laboratories focused on drug development and biomolecular research. The company's offerings include a variety of assay kits, antibodies, recombinant proteins, and polyclonal and monoclonal reagents, all supported by extensive references in scientific literature such as PubMed. Geographically, Biametrics serves a diverse international client base, including markets in North America, Europe, and Asia, addressing the growing demand for high-quality laboratory reagents and assays in the field of biomedical research and diagnostics.Biametrics Circadian Kronos generates revenue through direct sales and partnerships with research institutions and commercial laboratories. The company's pricing structure is tailored to meet the specific needs of its clients, offering a range of products that include proprietary assay kits and customized laboratory reagents. Transactions typically occur through B2B engagements, where institutional clients order various products based on their research requirements. The core offerings, including the Versa bscreen and associated assay kits, are priced according to the complexity and scale of the products, ensuring access to cutting-edge research tools for a wide array of applications. This structured approach positions Biametrics to maintain steady revenue streams while fostering long-term relationships with its diverse clientele.In February 2018, Biametrics raised EUR 3.10 mn in a Series A funding round to support the development of new products and technologies. The company has plans to expand into additional markets in North America and Asia by 2025, leveraging recent investments to enhance their product offerings and increase market presence. The funding will be used to accelerate product development and broaden geographic reach, aiding Biametrics in meeting the growing demand for their laboratory solutions.

## Funding rounds

- Series A, Aug 3, 2015, $3.4M — LBBW Venture Capital, High-Tech Gruenderfonds, MBG Schleswig-Holstein, KfW Mittelstandsbank
- Seed, Sep 30, 2010, $0.8M — LBBW Venture Capital, High-Tech Gruenderfonds, Kieffer & Co., Inc.

## Investors

- LBBW Venture Capital (https://capitalatlas.ai/funds/lbbw-venture-capital) — Seed, Series A
- High-Tech Gruenderfonds (https://capitalatlas.ai/funds/high-tech-gruenderfonds) — Seed, Series A
- Kieffer & Co., Inc. — Seed
- MBG Schleswig-Holstein (https://capitalatlas.ai/funds/mbg-schleswig-holstein) — Series A
- KfW Mittelstandsbank (https://capitalatlas.ai/funds/kfw-mittelstandsbank) — Series A